In Vitro Effects of Bevacizumab Treatment on Newborn Rat Retinal Cell Proliferation, Death, and Differentiation


Autoria(s): Miguel, Nadia C. O.; Matsuda, Monique; Portes, Andre Luis F.; Allodi, Silvana; Mendez-Otero, Rosalia; Puntar, Thiago; Sholl-Franco, Alfred; Krempel, Paloma G.; Monteiro, Mario L. R.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

05/11/2013

05/11/2013

2012

Resumo

PURPOSE. Vascular endothelial growth factor (VEGF) is an important signal protein in vertebrate nervous development, promoting neurogenesis, neuronal patterning, and glial cell growth. Bevacizumab, an anti-VEGF agent, has been extensively used for controlling pathological retinal neovascularization in adult and newborn patients, although its effect on the developing retina remains largely unknown. The purpose of this study was to investigate the effect of bevacizumab on cell death, proliferation, and differentiation in newborn rat retina. METHODS. Retinal explants of sixty 2-day-old Lister hooded rats were obtained after eye enucleation and maintained in culture media with or without bevacizumab for 2 days. Immunohistochemical staining was assessed against proliferating cell nuclear antigen (PCNA, to detect cell proliferation); caspase-3 and beclin-1 (to investigate cell death); and vimentin and glial fibrillary acidic protein (GFAP, markers of glial cells). Gene expressions were quantified by real-time reverse-transcription polymerase chain reaction. Results from treatment and control groups were compared. RESULTS. No significant difference in the staining intensity (on immunohistochemistry) of PCNA, caspase-3, beclin-1, and GFAP, or in the levels of PCNA, caspase-3, beclin-1, and vimentin mRNA was observed between the groups. However, a significant increase in vimentin levels and a significant decrease in GFAP mRNA expression were observed in bevacizumab-treated retinal explants compared with controls. CONCLUSIONS. Bevacizumab did not affect cell death or proliferation in early developing rat retina but appeared to interfere with glial cell maturation by increasing vimentin levels and downregulating GFAP gene expression. Thus, we suggest anti-VEGF agents be used with caution in developing retinal tissue. (Invest Ophthalmol Vis Sci. 2012;53:7904-7911) DOI:10.1167/iovs.12-10283

Rio de Janeiro State Foundation for the Advancement of Science (FAPERJ)

Rio de Janeiro State Foundation for the Advancement of Science (FAPERJ)

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Brazil

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Sao Paulo, Brazil [2011/50174-0]

Identificador

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ROCKVILLE, v. 53, n. 12, supl. 1, Part 1, pp. 7904-7911, NOV, 2012

0146-0404

http://www.producao.usp.br/handle/BDPI/41729

10.1167/iovs.12-10283

http://dx.doi.org/10.1167/iovs.12-10283

Idioma(s)

eng

Publicador

ASSOC RESEARCH VISION OPHTHALMOLOGY INC

ROCKVILLE

Relação

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

Direitos

closedAccess

Copyright ASSOC RESEARCH VISION OPHTHALMOLOGY INC

Palavras-Chave #ENDOTHELIAL GROWTH-FACTOR #INTRAVITREAL BEVACIZUMAB #CORNEAL NEOVASCULARIZATION #DIABETIC-RETINOPATHY #GANGLION-CELL #RABBIT EYES #AVASTIN #VEGF #INJECTION #EXPRESSION #OPHTHALMOLOGY
Tipo

article

original article

publishedVersion